The Investment You Can Make

In the late 1960s, the story goes, Warren Buffett was raising a new investment partnership in Omaha. He was not famous yet. He was a local man who had made his investors good money, and word traveled the way word travels in a mid-sized city. The women who knew him, who had watched him think clearly and speak plainly for years, put in amounts they could afford to lose. Some of them put in $10,000. Some put in $25,000. A few put in more. They were not analyzing float calculations or reading proxy statements. They were investing in someone they had watched operate, in something they understood to be real, in a person they trusted to tell them the truth about what he was building.

The analogy to the reader of this publication is imperfect in obvious ways. This is not a piece about Warren Buffett, and the reader is not being told to behave like his early investors. The analogy is about a specific kind of capital formation: the person who invests not because she has analyzed the technical details but because she has watched something be built honestly, understands what it is trying to do, and believes it should exist.

There is now a legal framework for that kind of investment at small scale, and the reader deserves to understand it clearly.

Regulation CF — Regulation Crowdfunding — was established by the JOBS Act of 2012 and allows companies to raise up to $5 million from non-accredited investors through SEC-registered platforms. Non-accredited means the investor does not have to meet the wealth or income thresholds required to invest in most private companies. A person with $40,000 in retirement savings and a $28,000 annual pension income can invest in a Regulation CF offering. The investment amount available to any individual investor is limited based on income and net worth, typically between $2,200 and $107,000 depending on financial situation.

Regulation A+ allows companies to raise up to $75 million from non-accredited investors through a more elaborate process that requires SEC qualification and audited financials. It is used by companies that have already established a track record and are seeking larger rounds from a broader investor base.

Both frameworks were designed to extend private investment access to people who are not wealthy, and both are now being used by companies in healthcare, aging technology, and care infrastructure.

The reader who invests through these frameworks is making a private investment in an early-stage or growth-stage company. This is categorically different from buying stock in a public company, putting money in a savings account, or buying a bond. The risk profile is also categorically different.

Two readers of this publication have made investments in aging technology companies. Both deserve a full account.

Miriam Tate, 69, a retired occupational therapist from Columbus, Ohio, invested $2,500 in a Regulation CF round for a remote patient monitoring company that integrated home health sensor data with clinical records. She found the offering through one of the SEC-registered crowdfunding platforms in 2022. She had read extensively about remote patient monitoring. She understood what the company was trying to build because she had spent thirty years working with patients who needed exactly what it was building. She evaluated the team, the product roadmap, and the business model. She invested the money she would have spent on a kitchen appliance she did not need. In 2024, the company was acquired by a larger care technology platform. Her $2,500 returned approximately $9,800. She donated the difference to a nursing scholarship at Ohio State.

Lucinda Morales, 71, a retired county clerk from San Antonio, invested $1,500 in a Regulation CF round for a senior companion app in 2021. The app was designed to address loneliness through scheduled video conversations with trained companions. Lucinda had read about the loneliness epidemic in older adults and believed that someone was addressing it seriously. The company had a compelling video, a charismatic founder, and testimonials from early users. In 2023, the company shut down after failing to secure Series A funding. Its technology was never integrated into a larger platform. Lucinda’s $1,500 is gone. She does not regret the investment, exactly, but she would evaluate it differently today.

Both stories are real patterns, generalized from the actual experience of non-accredited investors in care technology crowdfunding rounds between 2020 and 2024. Neither story is exceptional. They represent the two most common outcomes in early-stage investment in care technology: acquisition or failure. There is not much in between.

The risk section of any crowdfunding offering is required by the SEC to include specific language about the possibility of total loss. Read it. The language is not boilerplate in the way that terms-of-service agreements are boilerplate. It is an accurate description of what can happen.

Early-stage investment can lose everything. The company may fail to raise enough to execute its plan. The product may not achieve product-market fit. The clinical evidence may not support the business case. The regulatory environment may change. A well-capitalized competitor may enter the market and make the company’s position untenable. A bad leadership decision may destroy value that a good product had built. The reader on a fixed income should never invest money she cannot afford to lose. This is not a disclaimer. It is the accurate description of the risk she is accepting.

The temporal honesty this publication applies to technology claims applies equally to financial claims. A company that says it will be profitable in eighteen months may believe that statement when it makes it. The difference between a financial projection and financial performance is the same as the difference between a press release about an AI health tool and that tool’s validated clinical outcomes. Both are real statements about the future. Neither is reliable as a prediction. The reader who evaluates a crowdfunding investment should hold the company’s projections with the same skepticism she has learned to hold technology timelines.

The framework for evaluating any aging technology investment — not only one connected to this publication — has five questions.

What specific problem does this company solve, and for whom? The answer should be specific. “Improving aging at home” is not an answer. “Reducing medication errors for adults managing more than five chronic prescriptions through pharmacist-AI integration” is an answer. The more specifically you can describe the problem, the more specifically you can evaluate whether the company’s solution addresses it.

What evidence supports the solution? Clinical trial results, peer-reviewed research, published outcome studies, real-world data from deployed customers — these are evidence. Testimonials, advisor lists, partnership announcements, and letters of intent are not evidence. The difference between the two is the same difference BGM taught you to apply to press releases versus peer-reviewed research.

How does the company make money, and from whom? A company whose revenue comes from the people it serves has different incentives than a company whose revenue comes from institutional clients, advertisers, or data buyers. Understanding the business model is not a finance exercise. It is the question that tells you whose interests the company is structurally aligned with.

What happens to your money if the company fails? In most Regulation CF investments, you own equity shares that become worthless if the company shuts down. Some offerings include convertible notes with some downside protection. Read the offering document to understand the specific structure.

Can you afford to lose this amount? The answer has to be yes before the other four questions matter.

The Omaha housewives argument is not a recommendation to invest in any specific company. It is a description of a capital participation model that this publication believes is underused by the population it serves.

The reader who has followed BML for a year understands what integrated care looks like, what evidence-based technology means, what temporal honesty sounds like, and what a business model built for the reader’s interests rather than against them should produce. She has the evaluation framework that most individual investors do not have. If she applies that framework to an investment opportunity and concludes that the answer to all five questions is satisfactory, and if she can afford to lose the money, she is in a better position to make a sound small investment in aging care infrastructure than most institutional investors were when they first entered the category.

Her investment, if she makes it, does something Miriam Tate’s investment did and Lucinda Morales’s investment attempted: it aligns her financial interest with her care interest. If the company succeeds, she earns a return on an investment in something she will use. If it fails, she loses money she allocated to that possibility. Both outcomes are honest. Both outcomes are the right outcomes for an investor who evaluated the risk and made a considered decision.

The crowdfunding round is not the most important part of the capital architecture. Government funding is. Institutional investment is. But the reader who participates in the architecture that shapes her own future is not a passive consumer of policy decisions made in rooms she never entered. She is a stakeholder.